safety | CARLAT PUBLISHING

Expert Q&A

Understanding Suicide: Prevention and Intervention Strategies

April 1, 2024

J. John Mann, MD.

Paul Janssen Professor of Translational Neuroscience in Psychiatry and Radiology; Director, Molecular Imaging and Neuropathology Division; Co-Director, Columbia Center for Prevention and Treatment of Depression, Columbia University/New York State Psychiatric Institute, New York, NY.

Dr. Mann receives royalties from the Research Foundation for Mental Hygiene for the commercial use of the Columbia-Suicide Severity Rating Scale and royalties from Columbia University for the Columbia Psychiatry Pathways app. Relevant financial relationships listed for the author have been mitigated.

We examine effective suicide prevention techniques, highlighting simple yet impactful methods such as post-hospitalization follow-ups via phone calls or postcards. Dr. Mann offers insight into these and other interventions that have been successful in lowering suicide rates.

How to Interview the Older Patient

August 29, 2022

Stephanie Collier, MD and Rehan Aziz, MD.

The expanding population of older adults has created a need for all clinicians to participate in their care. Interviewing techniques require adaptation in older adults, such as accounting for hearing or vision impairment and speaking slowly and clearly. This podcast will cover additional factors to consider when evaluating older patients.

An Unexpected Opioid: Loperamide Misuse

May 21, 2021

Mara Storto, MD. and Deepti Anbarasan, MD.

Mara Storto, MD. Psychiatric Resident, Psychiatry Residency Training Program, New York University Langone Health, New York, NY. Deepti Anbarasan, MD. Clinical Assistant Professor of Psychiatry, New York University, New York, NY. Dr. Storto and Dr. Anbarasan have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

We normally think of loperamide as an over-the-counter drug with a good safety profile. And it is, but only when used as directed. Recreational misuse of loperamide is on the rise with some dangerous collateral effects.

Mood Stabilizers: What You Don’t Know Can Hurt Them

October 6, 2020

Nicholas Rosenlicht, MD.

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are many mood stabilizers to choose from, but which ones are the best tolerated? This meta-analysis looks at how they stack up in terms of weight gain, sedation, and overall discontinuation.

“What About the Implant, Doc?” Appraising Various Formulations of Buprenorphine

August 6, 2020

Edmund S. Higgins, MD.

Edmund S. Higgins, MD. Clinical Associate Professor of Psychiatry and Family Medicine, MUSC, Charleston, SC. Dr. Higgins has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Buprenorphine can be administered via intravenous, transdermal, sublingual, buccal, and implanted formulations. We appraise the evidence for various formulations and suggest certain populations for which certain formulations may be a better choice.

Transcranial Magnetic Stimulation (TMS) for Depression in Children and Adolescents

June 11, 2019

With concerns about both safety and efficacy surrounding antidepressant use in children and adolescents, we are always looking for safe, effective treatments for our patients. Transcranial Stimulation (TMS) has been around for many years, and its use in youth is expanding. We examine the evidence of efficacy and potential side effects in youth and adolescent populations.

First Non-Drug Treatment Approved by FDA for Treating Children With ADHD

June 11, 2019

Talia Puzantian, PharmD, BCPP and Joshua Feder, MD

Talia Puzantian, PharmD, BCPP Joshua Feder, MD Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In the article we discuss the effectiveness and safety of the first non-drug treatment for ADHD in kids. The FDA has recently granted medical device approval for its external Monarch Trigeminal Nerve Stimulation (eTNS) System for treating kids with ADHD ages 7–12 who are not currently taking medications.